Anthropic announced that Novartis CEO Vas Narasimhan has joined its board of directors. The appointment signals the AI company's deepening commitment to healthcare and life sciences applications.
Narasimhan's addition to Anthropic's board comes as the Claude chatbot maker expands its presence in the pharmaceutical and biotech sectors. Earlier this month, Anthropic acquired biotech startup Coefficient Bio for approximately $400 million.
The move reflects growing interest from major healthcare companies in artificial intelligence capabilities. Narasimhan brings decades of experience in pharmaceutical leadership and drug development, positioning him to guide Anthropic's healthcare initiatives.
Anthhropic has been building specialized tools for life sciences research, leveraging Claude's language capabilities for tasks including drug discovery support and scientific analysis. The Coefficient Bio acquisition accelerated these efforts by bringing in specialized biotech expertise.
Board appointments from pharmaceutical executives represent a significant vote of confidence from the healthcare industry in Anthropic's technology and direction. The partnership may also facilitate future collaborations between Anthropic and Novartis on AI applications in drug development and healthcare.
A comparative study found Claude Code consumes nearly five times more tokens than OpenCode before even processing user prompts, raising efficiency concerns for developers managing API costs.
A new study finds that AI tools are helping researchers advance their careers faster while simultaneously narrowing the range of ideas being explored. The research suggests AI adoption in science may be creating a homogenizing effect on academic discovery.
LinkedIn accounts for nearly two-thirds of all AI-generated long-form posts across major social platforms, according to a Pangram analysis. The platform's 41 percent AI-written rate far exceeds competitors despite making up only a third of all scanned posts.
The autonomous vehicle industry confronts mounting demands for real-world performance and regulatory compliance. Companies must prove viability or face increased scrutiny.